Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/1968| Convalescent plasma: A possible treatment of COVID-19 in India | |
| Teixeira da Silva Jaime A.. | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| 10.1016/j.mjafi.2020.04.006 | |
| In India, SARS-CoV-2 virus–induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti–SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection. | |
| Medical Journal Armed Forces India | |
| 2020 | |
| Artículo | |
| https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158785/pdf/main.pdf | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 1100686.pdf | 293 kB | Adobe PDF | Visualizar/Abrir |